Drugs that contain Ambrisentan
1. Letairis patents expiration
LETAIRIS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5703017 | GILEAD | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
Dec, 2014
(9 years ago) | |
| US7109205 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| US8349843 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| USRE42462 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7601730 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| US5840722 | GILEAD | Use of carboxylic acid derivatives as drugs |
Nov, 2015
(8 years ago) | |
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(3 years from now) | |
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(3 years from now) | |
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2012 |
| New Indication(I-716) | Oct 02, 2018 |
| Orphan Drug Exclusivity(ODE) | Jun 15, 2014 |
NCE-1 date: 16 June, 2011
Market Authorisation Date: 15 June, 2007
Treatment: Method to treat pulmonary hypertension by administering ambrisentan to a patient; Method of inhibiting enthothelin receptors by administering ambrisentan to a patient to treat pulmonary arterial hyper...
Dosage: TABLET;ORAL
How can I launch a generic of LETAIRIS before it's drug patent expiration?
More Information on Dosage
LETAIRIS family patents
